31P-MRS and Huntington Disease
Not Applicable
Completed
- Conditions
- Huntington Disease
- Registration Number
- NCT01359774
- Lead Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Brief Summary
The purpose of this study is to identify and quantify a brain energy deficit in Huntington patients, using 31P-RMN spectroscopy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- 5<UHDRS<50
- Age>18 years
- Ability to undergo MR scanning
- Covered by french social security
Exclusion Criteria
- Evidence of psychiatric disorder
- Attendant neurological disorder
- Contraindications to MRI (claustrophobia, metallic or material implants)
- Severe head injury
- Unable to understand the protocol
- Pregnancy
- Failure to give informed consent
- Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)
- Unwillingness to be informed in case of abnormal MRI
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Brain energy deficit in Huntington patients one year 31P-MRS allows quantification of high-energy phosphate metabolites such as ATP and phosphocreatine.
Objective: to look at brain energy metabolism during rest and activation.
- Secondary Outcome Measures
Name Time Method Correlating a brain energy deficit with (i) biochemical parameters and (ii) clinical parameters in Huntington patients one year Biochemical parameters include metabolites that we previously showed to be biomarkers in HD: branched chain amino acids and IGF1.
Clinical parameters include UHDRS and TFC.
Trial Locations
- Locations (1)
Hopital de la Pitié-Salpetrière
🇫🇷Paris, France
Hopital de la Pitié-Salpetrière🇫🇷Paris, France